Prostaglandin-mediated signaling in schizophrenia

International Review of Neurobiology

Volumn 59, Issue , 2004, Pages 255-271

  Smesny, S ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; NICOTINIC ACID; PHOSPHOLIPID; PROSTAGLANDIN;

ANIMAL; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN;

ANIMALS; HUMANS; NIACIN; PHOSPHOLIPIDS; PROSTAGLANDINS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN;

EID: 2342586082     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(04)59010-4     Document Type: Article

References (99)

1. Y.H. Abdullah K. Hamadah Effect of ADP on PGE formation in blood platelets from patients with depression, mania, and schizophrenia Br. J. Psychiat. 127 1975 591 595
2. R.G. Andersson G. Aberg R. Brattsand E. Ericsson L. Lundholm Studies on the mechanism of flush induced by nicotinic acid Acta Pharmacol. Toxicol. 41 1977 1 10
3. D.A. Basketter K.P. Wilhelm Studies on non-immune immediate contact reactions in an unselected population Cont. Dermat. 35 1996 237 240
4. N.G. Bazan M.J. Serou Second messengers, long-term potentiation, gene expression and epileptogenesis Adv. Neurol. 79 1999 659 664
5. G. Berger P. McGorry The topical niacin flush test: A new assessment scale World J. Biol. Psychiat. 2 2001 134S 135S
6. G.B. Berger S. Smesny H.P. Yuen S. Riemann P.D. McGorry The topical niacin flush test in early psychosis Schizophr. Res. 53 2002 S38
7. G.E. Berger S.J. Wood C. Pantelis D. Velakoulis R.M. Wellard P.D. McGorry Implications of lipid biology for the pathogenesis of schizophrenia Aust. N. Z. J. Psychiat. 36 2002 355 366
8. G.J. Bix G.D. Clark Platelet-activating factor receptor stimulation disrupts neuronal migration in vitro J. Neurosci. 18 1998 307 318
9. G. Calabrese R.F. Deicken G. Fein E.L. Merrin F. Schoenfeld M.W. Weiner 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia Biol. Psychiat. 32 1992 26 32
10. S.E. Carlson J.D. Carver S.G. House High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linoleic acid: A comparison of rat neural and red cell membrane phospholipids J. Nutr. 116 1986 718 725
11. C. Chen J.C. Magee V. Marcheselli Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor J. Neurophysiol. 85 2001 384 390
12. G. Chouinard L. Annable D.F. Horrobin An antipsychotic action of penicillin in schizophrenia IRCS J. Med. Sci. 6 1978 187
13. W.E. Connor D.S. Lin M. Nevringer Is the docosahexaenoic acid (DHA) content of erythrocytes a marker for the DHA content of brain phospholipids? FASEB J. 7 1993 A152
14. W.E. Connor M. Neuringer D.S. Lin Dietary effects on brain fatty acid composition: The reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys J. Lipid Res. 31 1990 237 247
15. U.N. Das Essential fatty acids, lipid peroxidation and apoptosis Prostagland. Leukot. Essent. Fatty Acids 61 1999 157 163
16. J. Deickert M.M. Nothen S.P. Bryant S. Schuffenhauer P.R. Schonfield N.K. Spurr P. Propping Mapping of the human adenosine A2a receptor gene: Relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region Hum. Genet. 99 1997 326 328
17. L. Demisch K. Heinz H. Gerbaldo R. Kirsten Increased concentrations of phosphatidylinositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizophrenic disorders or atypic phasic psychoses Prostagland. Leukot. Essent. Fatty Acids 46 1992 47 52
18. R.H. Dworkin Pain insensitivity in schizophrenia: A neglected phenomenon and some implications Schizophr. Bull. 20 1994 235 248
19. B. Eklund L. Kaiser J. Nomak A. Wenmalm Prostaglandins contribute to the vasodilatation induced by nicotinic acid Prostaglandins 17 1979 821 838
20. R. Emsley C. Myburgh P. Oosthuizen S.J. van Rensburg Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia Am. J. Psychiat. 159 2002 1596 1598
21. W. Feldberg Possible association of schizophrenia with a disturbance in prostaglandin metabolism: A physiological hypothesis Psychol. Med. 6 1967 359 369
22. W.S. Fenton J. Hibbeln M. Knable Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia Biol. Psychiat. 47 2000 8 21
23. P. Fiedler A. Wolkin J. Rotrosen Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics Biol. Psychiat. 21 1986 1347 1350
24. H. Fukuzako T. Fukuzako T. Hashiguchi S. Kodama M. Takigawa T. Fujimoto Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients Am. J. Psychiat. 156 1999 1205 1208
25. D.L. Garver J.A. Holcomb J.D. Christensen Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum J. Clin. Psychiat. 61 2000 964 972
26. W.F. Gattaz C.V. Hubner T.J. Nevalainen T. Thuren P.K. Kinnunen Increased serum phospholipase A2 activity in schizophrenia: A replication study Biol. Psychiat. 28 1990 495 501
27. W.F. Gattaz M. Kollisch T. Thuren J.A. Virtanen P.K. Kinnunen Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy Biol. Psychiat. 22 1987 421 426
28. W.F. Gattaz A. Schmitt A. Maras Increased platelet phospholipase A2 activity in schizophrenia Schizophr. Res. 16 1995 1 6
29. A.I. Glen S.J. Cooper J. Rybakowski K. Vaddadi N. Brayshaw D.F. Horrobin Membrane fatty acids, niacin flushing and clinical parameters Prostagland. Leukot. Essent. Fatty Acids 55 1996 9 15
30. A.I. Glen E.M. Glen D.F. Horrobin K.S. Vaddadi M. Spellman N. Morse-Fisher K. Ellis F.S. Skinner A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases Schizophr. Res. 12 1994 53 61
31. H. Hermesh R. Shiloh Y. Epstein H. Manaim A. Weizman H. Munitz Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs Am. J. Psychiat. 157 2000 1327 1329
32. A. Hoffer “Niacin Therapy in Psychiatry.” 1962 C. C. Thomas Springfield
33. D.F. Horrobin Schizophrenia as a prostaglandin deficiency disease Lancet 1 1977 936 937
34. D.F. Horrobin “Prostaglandins: Physiology, Pharmacology and Clinical Significance.” 1978 Eden Press Montreal
35. D.F. Horrobin Prostaglandin deficiency and endorphin excess in schizophrenia: The case for treatment with penicillin, zinc, and evening primrose oil Orthomol. Psychiat. 8 1979 13 19
36. D.F. Horrobin Schizophrenia: A biochemical disorder? Biomedicine 32 1980 54 55
37. D.F. Horrobin Schizophrenia as a membrane lipid disorder which is expressed throughout the body Prostagland. Leukot. Essent. Fatty Acids 55 1996 3 7
38. D.F. Horrobin The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia Schizophr. Res. 30 1998 193 208
39. D.F. Horrobin A.I. Ally R.A. Karmali M. Karmazyn M.S. Manku R.O. Morgan Prostaglandins and schizophrenia: Further discussion of the evidence Psychol. Med. 8 1978 43 48
40. D.F. Horrobin A.I. Glen K. Vaddadi The membrane hypothesis of schizophrenia Schizophr. Res. 13 1994 195 207
41. D.F. Horrobin M.S. Manku H. Hillman A. Iain M. Glen Fatty acid levels in the brains of schizophrenics and normal controls Biol. Psychiat. 30 1991 795 805
42. C.J. Hudson J.L. Kennedy A. Gotowiec Genetic variant near cytosolic phospholipase A2 associated with schizophrenia Schizophr. Res. 21 1996 111 116
43. C.J. Hudson A. Lin S. Cogan F. Cashman J.J. Warsh The niacin challenge test: Clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol. Psychiat. 41 1997 507 513
44. I. Illig Die Reaktion der Haut des Neurodermitikers auf zwei nicotinsäureesterhaltige Reizstoffe Dermatol. Wochenschr. 32 1952 753 763
45. M.S. Kafka D.P. van Kammen W.E., Jr. Bunney Reduced cyclic AMP production in the blood platelets from schizophrenic patients Am. J. Psychiat. 136 1979 685 687
46. H. Kaiya Prostaglandin E1 treatment of schizophrenia J. Clin. Psychopharmacol. 7 1987 357 358
47. H. Kaiya M. Ofuji M. Nozaki K. Tsurumi Platelet prostaglandin E1 hyposensitivity in schizophrenia: Decrease in cyclic AMP formation and in inhibitory effects on aggregation Psychopharmacol. Bull. 26 1990 381 384
48. M.S. Keshavan J.W. Pettegrew K.S. Panchalingam D. Kaplan E. Bozik Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia Arch. Gen. Psychiat. 48 1991 1112 1113
49. A. Kudoh H. Ishihara A. Matsuki Current perception thresholds and postoperative pain in schizophrenic patients Reg. Anesth. Pain Med. 25 2000 475 479
50. J. Lasch I. Willhardt D. Kinder H. Sauer S. Smesny Fluorometric assays of phospholipase A2 activity using three different substrates: Heterogeneous results in blood samples of schizophrenia patients and matched controls due to methodological reasons Clin. Chem. Lab. Med. 4 2003 908 914
51. S.Y. Lim H. Suzuki Effect of dietary docosahexaenoic acid and phosphatidylcholine on maze behaviour and fatty acid composition of plasma and brain lipids in mice Int. J. Vitam. Nutr. Res. 70 2000 251 259
52. S. Lipper D.S. Werman Schizophrenia and intercurrent physical illness: A critical review of the literature Compr. Psychiat. 18 1977 11 22
53. S.P. Mahadik S. Mukherjee R. Scheffer E.E. Correnti J.S. Mahadik Elevated plasma lipid peroxides at the onset of nonaffective psychosis Biol. Psychiat. May 43 1998 674 679
54. E. Messamore W.F. Hoffman A. Janowsky The niacin skin flush abnormality in schizophrenia: A quantitative dose-response study Schizophr. Res. 62 2003 251 258
55. J.D. Morrow J.A. Awad J.A. Oates L.J.D. Roberts Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans J. Invest. Dermatol. 98 1992 812 815
56. J.D. Morrow W.G.D. Parsons L.J.D. Roberts Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid Prostaglandins 38 1989 263 274
57. S. Mukerjee S.P. Mahadik R. Scheffer E.E. Correnti H. Kelkar Impaired antioxidant defends at the onset of psychosis Schizophr. Res. 19 1996 19 26
58. M. Murakami T. Kambe S. Shimbara I. Kudo Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways J. Biol. Chem. 274 1999 3103 3115
59. M. Murakami R. Matsumoto Y. Urade K.F. Austen J.P. Arm c-kit ligand mediates increased expression of cytosolic phospholipase A2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D2 synthase and increased IgE-dependent prostaglandin D2 generation in immature mouse mast cells J. Biol. Chem. 270 1995 3239 3246
60. M. Ofuji H. Kaiya M. Nozaki K. Tsurumi Platelet prostaglandin E1 hyposensitivity in schizophrenia: Reduction of prostaglandin E1- or forskolin-stimulated cyclic AMP response in platelets Life Sci. 45 1989 2135 2140
61. R.J. Oken M. Schulzer Schizophrenia and rheumatoid arthritis: The negative association revisited Schizophr. Bull. 25 1999 625 638
62. G.N. Pandey D.L. Garver C. Tamminga S. Ericksen S.I. Ali J.M. Davis Postsynaptic supersensitivity in schizophrenia Am. J. Psychiat. 134 1977 518 522
63. A.M. Pangerl A. Steudle H.W. Jaroni R. Rufer W.F. Gattaz Increased platelet membrane lysophosphatidylcholine in schizophrenia Biol. Psychiat. 30 1991 837 840
64. M. Peet J. Laugharne N. Rangarajan D. Horrobin G. Reynolds Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients J. Psychiatr. Res. 29 1995 227 232
65. M. Peet C.N. Ramchand J. Lee S.D. Telang G.K. Vankar S. Shah J. Wei Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia Psychiatr. Genet. 8 1998 191 192
66. J.W. Pettegrew M.S. Keshavan K. Panchalingam S. Strychor D.B. Kaplan M.G. Tretta M. Allen Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics: A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy Arch. Gen. Psychiat. 48 1991 563 568
67. K.A. Pontus L. Forsell B.P. Kennedy H.-E. Claesson The human calcium-independent phospholipase A2 gene: Multiple enzymes with distinct properties from a single gene Eur. J. Biochem. 262 1999 575 585
68. B.K. Puri A.J. Richardson T. Easton Association of niacin flush response with schizophrenia symptoms Schizophr. Res. 41 2000 251
69. C.V. Rao B. Simi T.T. Wynn K. Garr B.S. Reddy Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats Cancer Res. 56 1996 532 537
70. B.M. Ross C. Hudson J. Erlich J.J. Warsh S.J. Kish Increased phospholipid breakdown in schizophrenia: Evidence for the involvement of a calcium-independent phospholipase A2 Arch. Gen. Psychiat. 54 1997 487 494
71. B.M. Ross S. Turenne A. Moszczynska J.J. Warsh S.J. Kish Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia Brain Res. 821 1999 407 413
72. J. Rotrosen A.D. Miller D. Mandio L.J. Traficante S. Gershon Reduced PGE1 stimulated 3H-cAMP accumulation in platelets from schizophrenics Life Sci. 23 1978 1989 1996
73. J. Rybakowski R. Weterle Niacin test in schizophrenia and affective illness Biol. Psychiat. 29 1991 834 836
74. R.D. Schwarz N.J. Uretsky J.R. Bianchine Prostaglandin inhibition of amphetamine-induced circling in mice Psychopharmacology 78 1982 317 321
75. S.H. Shah G.K. Vankar M. Peet C.N. Ramchand Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin Schizophr. Res. 43 2000 163 164
76. T. Shioiri T. Kato T. Inubushi J. Murashita S. Takahashi Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia Psychiat. Res. 55 1994 223 235
77. S. Smesny G. Berger T. Rosburg S. Riemann S. Riehemann P. McGorry H. Sauer Potential use of the topical niacin skin test in early psychosis: A combined approach using optical reflection spectroscopy and a descriptive rating scale J. Psychiatr. Res. 37 2003 237 247
78. S. Smesny S. Riehemann J. Lasch R. Koelsch H.-P. Volz H. Sauer Schizophrenia—A systemic dysregulation of lipid metabolism: Preliminary results of a 31P-nuclear magnetic resonance spectroscopy- and phospholipase A2 -activity investigation Eur. J. Neurosci. 12 S11 2000 423
79. S. Smesny S. Riemann S. Riehemann M.E. Bellemann H. Sauer Quantitative measurement of induced skin reddening using optical reflection spectroscopy: Methodology and clinical application Biomed. Tech. 46 2001 280 286
80. S. Smesny T. Rosburg S. Riemann H. Sauer Altered prostaglandin mediated skin flush in schizophrenia: Implications for early psychosis interventions B.F. Szuhaj W. van Nieuwenhuyzen “Nutrition and Biochemistry of Phospholipids” 2003 AOCS Press Champaign, Il 2003
81. J.A. Stanley P.C. Williamson D.J. Drost T.J. Carr R.J. Rylett S. Morrison-Stewart R.T. Thompson Membrane phospholipid metabolism and schizophrenia: An in vivo 31P-MR spectroscopy study Schizophr. Res. 13 1994 209 215
82. H., Jr. Tavares J. Yacubian L.L. Talib N.R. Barbosa W. Gattaz Increased phospholipase A2 activity in schizophrenia with absent response to niacin Schizophr. Res. 61 2003 1 6
83. A. Tay J.S. Simon J. Squire K. Hamel H.J. Jacob K. Skorecki Cytosolic phospholipase A2 gene in human and rat: Chromosomal lokalisation and polymorphic markers Genomics 26 1995 138 141
84. J.D. Terwilliger J. Ott A haplotype-based “haplotype relative risk” approach to detecting allelic associations Hum. Hered. 42 1992 337 346
85. K.L. Thomas M. Huttunen Neural migration, pro-inflammatory interleukins and periventricular leukomalacia: Involvement in schizophrenia Trends Neurosci. 1 22 1999 389 390
86. Y. Urade M. Ujihara Y. Horiguchi K. Ikai O. Hayaishi The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells: Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues J. Immunol. 143 1989 2982 2989
87. K.S. Vaddadi Penicillin and essential fatty acid supplementation in schizophrenia Prostagland. Med. 2 1979 77 80
88. K.S. Vaddadi P. Courtney C.J. Gilleard M.S. Manku D.F. Horrobin A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia Psychiatr. Res. 27 1989 313 323
89. P.E. Ward Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders Prostagland. Leukot. Essent. Fatty Acids 63 2000 65 68
90. P.E. Ward J. Sutherland E.M. Glen A.I. Glen Niacin skin flush in schizophrenia: a preliminary report Schizophr. Res. 29 1998 269 274
91. A. Wieraszko G. Li E. Kornecki Long-term potentiation in the hippocampus induced by platelet-activating factor Neuron 10 1993 553 557
92. J.K. Wilkin Chlorpropamide-alcohol flushing, malar thermal circulation index, and baseline malar temperature Metabolism 31 1982 948 958
93. J.H. Williams M.L. Errington M.A. Lynch Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus Nature 341 1998 739 742
94. D.W. Wilson A.B. Douglass Niacin skin flush is not diagnostic of schizophrenia Biol. Psychiat. 21 1986 974 977
95. J.K. Yao S. Leonard R.D. Reddy Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients Schizophr. Res. 42 2000 7 17
96. J.K. Yao J.A. Stanley R.D. Reddy Correlation between RBC fatty acids and 31P MRS brain measures in schizophrenia Soc. Biol. Psychiat. 47 2000 41
97. J.K. Yao D.P. van Kammen Incorporation of 3H-arachidonic acid into platelet phospholipids of patients with schizophrenia Prostagland. Leuko. Essent. Fatty Acids 55 1996 21 26
98. J.K. Yao P. Yasaei D.P. van Kammen Increased turnover of platelet phosphatidylinositol in schizophrenia Prostagland. Leukot. Essent. Fatty Acids 46 1992 39 46
99. G.S. Zubenko B.M. Cohen A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines Psychopharmacology 88 1986 230 236